Abbvie and Genentech join TrumpRx: 61 drugs, and one new price shock
Abbvie is now set to become part of a widening experiment in prescription pricing, and the timing matters. Two more pharmaceutical companies are expected to officially start selling selected commercial medications on the White House’s discounted pharmaceutical site as soon as Monday, adding fresh momentum to TrumpRx. The move puts a sharper spotlight on who benefits from the discounts, how the prices are structured, and whether the administration’s broader healthcare push can move from announcement to implementation.
Abbvie, TrumpRx, and the discount mechanism
American pharmaceutical companies Abbvie and Genentech will become the 10th and 11th companies to provide prescriptions at reduced rates on TrumpRx. Abbvie struck a deal with the Trump administration in January to cut the cost of certain medicines, and one of the drugs set to appear on the site is Humira, used to treat rheumatoid arthritis, Crohn’s disease and ulcerative colitis. The listed discount is 86%.
On the site, the prescription prices are available only to patients who are uninsured, or whose insurance does not cover the drug, and who must pay the full list price out of pocket. Patients with insurance coverage generally already pay lower prices, which makes the TrumpRx model less a universal rebate system than a targeted discount channel for a narrower group. That distinction is central to understanding what the platform does — and what it does not do.
What the new pricing says about the White House strategy
The White House official framework described the effort as part of a broader attempt to lower prescription drug prices through “most-favored-nation” agreements, under which companies sell medications to uninsured U. S. consumers at the same prices available in other countries. In practical terms, TrumpRx is becoming a test case for whether negotiated consumer-facing discounts can be scaled without waiting for a full legislative overhaul.
The numbers already show the scope of the effort. TrumpRx now sells over 61 drugs at a lower price, up from about 40 offerings when the website went live in February. For Abbvie, the most visible example is Humira Pen, also called adalimumab, which can cost over $6, 900 for uninsured individuals. On TrumpRx, coupons for Humira are expected to drop that price to $950, sharpening the contrast between list price and discounted price.
The administration is also working to codify the deals with the “Great Healthcare Plan, ” with the stated goal of allowing people on government insurance to use copays for TrumpRx drugs. Congress has not taken up that plan yet, leaving the policy on uncertain ground even as the site expands.
Genentech’s role and the broader pharmaceutical ripple effect
Genentech’s addition reinforces that TrumpRx is not a one-company pilot. The White House announced a deal with Genentech in December to reduce the cost of Xofluza, a single-dose pill used to treat and prevent the flu. That prescription will cost around $50, down from $168, based on the White House official’s figures.
Another drug company, Amgen, is also expanding its TrumpRx offerings to include Enbrel for arthritis and Otezla for plaque psoriasis. Taken together, the expansion suggests the site is being built through a sequence of company-specific deals rather than a single, systemwide pricing reset. That may help the administration show progress quickly, but it also leaves open questions about consistency, eligibility, and how far the model can go.
Expert perspective on the policy stakes
White House officials are presenting the expansion as proof that lower prices can be negotiated directly into the market for certain consumers. The stated objective is to make prescription drugs more accessible for uninsured patients and, if the broader plan advances, for some people on government insurance as well.
The most important issue now is not whether discounts exist, but whether they are durable and broad enough to matter beyond headline prices. Abbvie’s presence on TrumpRx will likely be read as a signal that more large manufacturers are willing to enter the framework, but the structure still depends on who qualifies and whether Congress acts on the administration’s larger proposal.
Regional and global impact of the Abbvie move
The administration’s “most-favored-nation” approach ties domestic prices to levels available in other countries, making the Abbvie discount part of a wider policy argument about international price gaps. That gives TrumpRx significance beyond a single website: it is being used as a vehicle to test whether the United States can force lower out-of-pocket prices for selected drugs without changing the insurance system first.
For patients facing high cash prices, the site may offer visible relief. For the broader healthcare market, the larger question is whether these company-by-company deals will remain limited to uninsured consumers or evolve into a more permanent pricing structure. Abbvie’s launch on TrumpRx may be another step forward, but the real test is whether the discount model can survive the gap between executive action and legislation.
With more companies joining TrumpRx and the administration still trying to codify the plan, the open question is whether this model becomes a pricing breakthrough or simply another temporary path around the system.
